Payment overview · 2025
General Payments
$276,867.82
175 reported records · 15 companies
Healthcare provider profile · identity verified
Wilber Wei-Poh Su, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · STANFORD, CA · NPI 1689618084
Verified facts
What the public records show
CMS Open Payments records show Wilber Wei-Poh Su, MD received $276,867.82 in general payments during 2025 across 175 reported records.
Boston Scientific Corporation accounted for 68.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $190,700.74 | 68.9% | 127 | 2025 |
| Synaptic Medical Corporation | Unresolved — no canonical attribution shown | $81,481.22 | 29.4% | 6 | 2025 |
| AltaThera Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $2,114.27 | 0.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $638.04 | 0.2% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$500.80 | 0.2% | 4 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $409.38 | 0.1% | 7 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $244.54 | 0.1% | 14 | 2025 |
| Volta Medical Inc | Unresolved — no canonical attribution shown | $180.00 | 0.1% | 1 | 2025 |
| Elutia, Inc. | Unresolved — no canonical attribution shown | $175.00 | 0.1% | 1 | 2025 |
| Vektor Medical Inc. | Unresolved — no canonical attribution shown | $169.67 | 0.1% | 1 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $158.34 | 0.1% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $33.70 | 0.0% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $27.09 | 0.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.69 | 0.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.34 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $141,750.00 | 40 |
| Consulting Fee | $96,976.14 | 10 |
| Travel and Lodging | $30,817.22 | 40 |
| Food and Beverage | $7,324.46 | 85 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $103,163.21 | 60 | 2025 |
Source payment records
|
|||||
| General - EP Normalized: general ep |
Device | Boston Scientific Corporation | $45,775.40 | 17 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $35,568.50 | 33 | 2025 |
Source payment records
|
|||||
| Clinical Trial Product Normalized: clinical trial product |
Device | Boston Scientific Corporation | $4,422.17 | 3 | 2025 |
Source payment records
|
|||||
| Sotalol Hydrochloride Normalized: sotalol hydrochloride |
Drug | AltaThera Pharmaceuticals LLC | $2,114.27 | 3 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $1,056.98 | 7 | 2025 |
Source payment records
|
|||||
| Rhythmia Mapping System Normalized: rhythmia mapping system |
Device | Boston Scientific Corporation | $551.02 | 5 | 2025 |
Source payment records
|
|||||
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $500.80 | 4 | 2025 |
Source payment records
|
|||||
| ENSITE Normalized: ensite |
Device | Abbott Laboratories | $377.20 | 4 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $365.62 | 6 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $244.54 | 14 | 2025 |
Source payment records
|
|||||
| VX1 Normalized: vx1 |
Device | Volta Medical Inc | $180.00 | 1 | 2025 |
Source payment records
|
|||||
| ECM Patch,Pouch Normalized: ecm patch pouch |
Device | Elutia, Inc. | $175.00 | 1 | 2025 |
Source payment records
|
|||||
| vMap Normalized: vmap |
Device | Vektor Medical Inc. | $169.67 | 1 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $158.34 | 1 | 2025 |
Source payment records
|
|||||
| ENSITE PRECISION Normalized: ensite precision |
Device | Abbott Laboratories | $147.46 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $143.20 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $113.38 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $33.70 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $33.70 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $33.70 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $27.09 | 1 | 2025 |
Source payment records
|
|||||
| LATITUDE Communicator Power Supply Normalized: latitude communicator power supply |
Device | Boston Scientific Corporation | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Flecainide Acetate | Flecainide Acetate | 98 | 37 |
| Eliquis | Apixaban | 70 | 25 |
| Xarelto | Rivaroxaban | 46 | 15 |
| Atenolol | Atenolol | 28 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 26 | 12 |
| Carvedilol | Carvedilol | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | 12 |
| Amlodipine Besylate | Amlodipine Besylate | 18 | suppressed |
| Furosemide | Furosemide | 18 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 17 | 15 |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Lisinopril | Lisinopril | 13 | suppressed |
| Losartan Potassium | Losartan Potassium | 13 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $276,867.82 · 175 records | Boston Scientific Corporation | AFFERA MAPPING SYSTEM, CARTO 3, Clinical Trial Product, ECM Patch,Pouch, EMBLEM MRI S-ICD, ENSITE, ENSITE PRECISION, FARAPULSE, GALLANT, General - EP, General - Therapies, LATITUDE Communicator Power Supply, LEQVIO, MYNX CONTROL VENOUS, OPSUMIT, OPSYNVI, Ohtuvayre, Optimizer, Rhythmia Mapping System, Sotalol Hydrochloride, UPTRAVI, VX1, WATCHMAN FLX, vMap | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error